A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses

Kathleen Medora / aacr - A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses PHILADELPHIA – A vaccine targeting common KRAS mutations was safe and stimulated KRAS-specific T-cell responses in 90% of study participants who…

AI Summary: An experimental KRAS-targeting vaccine administered to people at high risk for pancreatic cancer proved safe and generated durable immune responses, suggesting a credible path toward interception of pancreatic ductal adenocarcinoma before it takes hold. Researchers report sustained antibody and/or T-cell activity, supporting further development and larger efficacy trials.